PT - JOURNAL ARTICLE AU - Rabezanahary, Henintsoa AU - Gilbert, Caroline AU - Santerre, Kim AU - Scarrone, Martina AU - Gilbert, Megan AU - Thériault, Mathieu AU - Brousseau, Nicholas AU - Masson, Jean-François AU - Pelletier, Joelle N. AU - Boudreau, Denis AU - Trottier, Sylvie AU - Baz, Mariana TI - Live virus neutralizing antibodies against pre and post Omicron strains in food and retail workers in Québec, Canada AID - 10.1101/2023.09.03.23294976 DP - 2023 Jan 01 TA - medRxiv PG - 2023.09.03.23294976 4099 - http://medrxiv.org/content/early/2023/09/03/2023.09.03.23294976.short 4100 - http://medrxiv.org/content/early/2023/09/03/2023.09.03.23294976.full AB - Objectives To assess the neutralization activity pre and post Omicron BA.1 emergence in a unique cohort of 280 vaccinated restaurant/bar, grocery and hardware store workers in Québec, Canada.Methods Participants were recruited during the emergence of Omicron BA.1 variant. The neutralizing activity of participant sera was assessed by microneutralization assay.Results Serum neutralizing antibody (NtAb) titers of all participants against the ancestral SARS-CoV-2 strain was comparable with the response against Delta variant, however, their response was significantly reduced against Omicron BA.1, BA2, BA.2.12.1, BA.4 and BA.5. The neutralizing response of each group of workers was similar. Individuals who received 2 doses of vaccine had significantly reduced NtAb titers against all SARS-CoV-2 strains compared to those infected and then vaccinated (≥1 dose), vaccinated (≥2 doses) and then infected, or those who received 3 doses of vaccine. Participants vaccinated with 2 or 3 doses of vaccine and then infected had the highest NtAb titers against all SARS-CoV-2 strains tested.Conclusion We assessed for the first time the NtAb response in food and retail workers. Individuals infected after ≥2 doses of vaccine had the highest levels of NtAbs against Omicron BA.1, BA.2 and BA.5 variants and might be better protected against reinfection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Public Health of Canada through the COVID‐19 Immunity Task Force (CITF) to CG, JP, JFM, DB, ST and MB and the Sentinel North Research Chair at Universite Laval (funded by the Canada First Research Excellence Fund) as well as the Canada Research Chair to M.B.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:CHU de Quebec-Universite Laval Research Ethics Board (registration number 2021-5744)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript